ArticleBMC pulmonary medicine2025
Risk factors of incident lung diseases and the impact of DMARDs in rheumatoid arthritis patients: a longitudinal study.
Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- High baseline neutrophil-to-lymphocyte ratio is associated with better adalimumab response in patients with rheumatoid arthritis.The Journal of international medical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
objectiveWe aimed to investigate the impact of clinical characteristics and therapy on rheumatoid arthritis (RA)-related lung diseases.
methodsThe retrospective cohort consisted of 1,207 inpatients at baseline. RA-related lung diseases included interstitial lung disease (ILD), bronchiectasis, pleural effusion, and pulmonary arterial hypertension. Kaplan-Meier method was used to measure the cumulative incidence curve. Cox regression was conducted to evaluate the associations between RA-related lung diseases and risk indicators. Logistic regression was employed to examine the impact of drugs.
resultsThe study identified 145 cases of RA-related lung diseases (34.2/1,000 person-years; 95% CI: 28.6–39.7) and 98 RA-ILD cases (22.5/1,000 person-years; 95% CI: 18.0–26.9) over 3.5 years. The cumulative incidence of RA-related lung diseases increased continuously over time, accelerating after 10 years of RA and age 55. RA-related lung diseases was independently associated with older age at RA onset (per 10 years, hazard ratio [HR] = 1.22, 95% confidence interval [CI]: 1.04–1.42), longer RA duration (per 10 years, HR = 1.43, 95% CI: 1.15–1.77), higher Rheumatic Disease Comorbidity Index (HR = 1.22, 95% CI: 1.08–1.39), prior pulmonary infections (HR = 2.26, 95% CI: 1.58–3.24), and systemic lupus erythematosus comorbidity (HR = 2.36, 95% CI: 1.35–4.13). After adjustment, ever-use of methotrexate demonstrated a significant protective association against both RA-related lung diseases (odds ratio [OR] = 0.64, 95% CI: 0.44–0.92) and RA-ILD (OR = 0.54, 95% CI: 0.35–0.83). Similarly, biologic or targeted synthetic disease modifying antirheumatic drugs (b/tsDMARDs) were also found protective (OR = 0.59, 95% CI: 0.35–0.99).
conclusionThis study identifies several clinically significant risk factors for RA-related lung diseases, while demonstrating protective effects of methotrexate and b/tsDMARDs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.